Clinical Trial Update: Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for GR1603 in systemic lupus erythematosus (Phase 1/Phase 2) evaluating safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GR1603 (GR1603)

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Lupus Erythematosus, Systemic | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING